Skip to main content
Clinical Trials/EUCTR2016-000136-17-DE
EUCTR2016-000136-17-DE
Active, not recruiting
Phase 1

Prospective, randomized, multicenter clinical trial on the impact of Therapeutic Drug Monitoring (TDM) of piperacillin on organ functions and survival in the treatment of severe sepsis or septic shock - Target

Friedrich Schiller University Jena0 sites276 target enrollmentApril 8, 2016

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients with a severe sepsis oder a septic shock treatet with piperacillin/tazobactam
Sponsor
Friedrich Schiller University Jena
Enrollment
276
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 8, 2016
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Friedrich Schiller University Jena

Eligibility Criteria

Inclusion Criteria

  • Patients with severe sepsis or septic shock
  • onset of severe sepsis or septic shock not longer than 24 hours prior to randomization
  • Antimicrobial therapy with piperacillin planned or started
  • age \=18 years
  • written informed consent of the patient or legal representative
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 176
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • pregnant or breast\-feeding women
  • anamnestic known hypersensitivity against beta\-lactam antibiotics or another part of the investigational medicinal product
  • previous treatment with piperacillin (in combination with tazobactam) \> 24 hours before randomization
  • participation in another interventional clinical trial
  • previous participation (TARGET)
  • limits of therapy or cessation
  • impaired liver function (Child\-Pugh C)
  • life expectancy \< 28 day due to accompanying illnesses
  • piperacillin\-measurement impossible within 24 hours after randomization

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Multicenter, prospective, randomized clinical trial to assess two different doses of anti-human-T-lymphocyte immune serum preparation derived from rabbit in GVHD profilaxis in pediatric population with haematologic malignancies riceiving non allogenic stem cell transplantation. - NDgraft versus host disease profilactic useMedDRA version: 9.1Level: LLTClassification code 10018653Term: Graft-versus-host disease <GVHD>
EUCTR2008-000101-11-ITOSPEDALE POLICLINICO S. MATTEO
Active, not recruiting
Not Applicable
Healing effectiveness of Algosteril vs Aquacel Extra in pilonidal sinuses
ISRCTN24794558Brothier (France)238
Active, not recruiting
Not Applicable
A study Protocol for patients with relapsed osteosarcomaHigh malignancy grade of osteosarcoma relapseMedDRA version: 14.1Level: PTClassification code 10031296Term: Osteosarcoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2012-001010-42-ITITALIAN SARCOMA GROUP
Active, not recruiting
Not Applicable
Study comparing the use of a medical procedure (endoscopic band ligation) versus a drug treatment (carvedilol) to prevent bleeding of esophageal varices in patients with liver disease.Esophageal variceal bleeding in patients with cirrhosisTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2011-006208-11-ESCAIBER
Recruiting
Not Applicable
Effectiveness of Bi-Sai-Tong solution for moderate to severe allergic rhinitis: a randomized controlled study
ITMCTR1900002527Guangdong Provincial Hospital of Chinese Medicine